Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation

Cancer treatments often require combinations of molecularly targeted agents to be effective. mTORi (rapamycin) and HDACi (MS-275/entinostat) inhibitors have been shown to be effective in limiting tumor growth, and here we define part of the cooperative action of this drug combination. More than 60 h...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mol Cancer Ther
Main Authors: Simmons, John K., Michalowski, Aleksandra M., Gamache, Benjamin J., DuBois, Wendy, Patel, Jyoti, Zhang, Ke, Gary, Joy, Zhang, Shuling, Gaikwad, Snehal, Connors, Daniel, Watson, Nicholas, Leon, Elena, Chen, Jin-Qiu, Kuehl, W. Michael, Lee, Maxwell P., Zingone, Adriana, Landgren, Ola, Ordentlich, Peter, Huang, Jing, Mock, Beverly A.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5587368/
https://ncbi.nlm.nih.gov/pubmed/28522584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0171
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki